Stockreport

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics, Inc.  (LYRA) 
PDF – Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATE [Read more]